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Dengue fever is the most common tropical disease, but there still remains no specific therapy that can overcome it. Special 
attention needs to be paid to this disease, because there were large increases in incidence in the last decade. As an effective 
preventive strategy, finding a new vaccine for dengue fever with higher potentiation and efficacy is highly necessary to stop 
dengue transmission especially in the endemic area. Vaccine triggers an immune response, so that it can create a robust 
immune response when infected. Nowadays, there is only one licensed dengue vaccine that is CYD-TDV (Dengvaxia). However, 
this vaccine still has many weaknesses, namely its dependency on the serostatus of the recipient. There are also other dengue 
vaccines that are in ongoing clinical testing and have promising results, TDV (TAK-003) and TV003/TV005. These three 
vaccines are live attenuated vaccines with various results. This review discussed differences in the efficacy of CYD-TDV 
against the other TAK-003 and TV003/TV005; considering the known and unknown various factors.  
 




Demam dengue merupakan penyakit tropis yang sering terjadi, namun masih belum ada terapi spesifik untuk mengatasinya. 
Perhatian khusus perlu diberikan pada penyakit ini, karena terdapat peningkatan insiden yang signifikan pada dekade terakhir. 
Penemuan vaksin baru demam dengue dengan potensi dan efektivitas yang diperlukan merupakan salah satu strategi 
pencegahan efektif yang diperlukan untuk memutus mata rantai penularan demam berdarah/ dengue terutama di daerah 
endemik. Vaksin memicu respons imun, sehingga dapat menciptakan respons imun yang kuat saat terinfeksi. Saat ini, hanya 
ada satu vaksin dengue berlisensi yaitu CYD-TDV (Dengvaxia). Vaksin ini memiliki kelemahan, yaitu efikasi tergantung pada 
serostatus penerima. Terdapat vaksin dengue lain yang sedang menjalani uji klinis dan memiliki hasil yang menjanjikan, TDV 
(TAK-003) dan TV003/TV005. Ketiga vaksin ini merupakan vaksin hidup yang dilemahkan dengan hasil yang beragam. Ulasan 
ini membahas perbedaan kemanjuran CYD-TDV terhadap TAK-003 dan TV003/TV005 lainnya; mempertimbangkan berbagai 
faktor yang diketahui dan tidak diketahui. 
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Dengue is an infectious disease caused by dengue virus 
(DENV) which is transmitted through the bite of Aedes 
mosquitoes (especially Aedes aegypti), and it is one of 
the most common tropical diseases in the world. DENV 
is a single chain positive RNA virus consisting of four 
serotypes (DENV 1, DENV 2, DENV 3, and DENV 4), 
belongs to the Flaviviridae family, Flavivirus genus 
(including Zika, yellow fever, Japanese Encephalitis) 
(Wang et al. 2020). Someone who has been infected 
with DENV will have lifetime immunity against the 
same DENV serotype. It means that a person during his 
life can be infected four times. Dengue can be found in 
the tropical and subtropical countries of the world, 
especially in endemic countries with 10% of fever 
episodes that are caused by dengue (Wilder-Smith 
2020). The incidence of dengue has increased in the last 
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decade. A recent study discovered that the infection 
incidence is 390 million per year, of which 96 million 
experienced clinical symptoms (in varying degrees). 
The incidence rate was 8-fold compared to the last two 
decades (from 505.430 cases in 2000 to 4.2 million by 
2019) (World Health Organization 2014). Another study 
estimates that 3,900 million people are at risk to have 
dengue infection. This rapid increase is due to several 
factors, such as the increasing population, increasing 
urbanization and migration including international 
travel, global climate change, and difficulty to 
overcome vectors effectively and sustainably (Pinheiro-
Michelsen et al. 2020, Murray et al. 2013). 
 
Nowadays, there remains no specific treatment to cure 
dengue. The number of individuals who are at risk of 
getting dengue makes this disease highly important to 
be treated. The most effective strategy to overcome 
dengue is preventive, and is currently done by doing 
vector control. Yet, the control of this vector is 
sufficiently complex, because it is multidisciplinary and 
multi sector that can consume a lot of money and work 
(Da Silveira et al. 2019), so that the development of 
effective and safe dengue vaccine is an urgent necessity. 
The ideal dengue vaccine is a vaccine given in single 
doses that can protect against all four DENV serotypes, 
providing long-term protection, and having no side 
effects. The recognized dengue vaccine has related 
problems to the immune response and cross-reactive T-
cell responses implicated in a dysfunctional immune 
response that may contribute to more severe cases of 
secondary DENV infection. However, more recent 
works point to the value of more robust T-cell immunity 
in reducing the risk of developing severe manifestations 
of DENV infection (Collins & Metz 2017). 
 
 
MATERIALS AND METHODS 
 
This study was a systematic literature review conducted 
by collecting a number of literatures related to the 
problem and research objectives. In this study, we 
searched journal articles about dengue vaccines and its 
characteristics, efficacy, safety, and clinical trials status 
by reading it to make a theoretical summary, so that a 





There were several vaccines that had entered the clinical 
trial phase, namely TV003/TV005, TDV/DENVax 
(TAK-003), PIV, V180, D1ME100, TVDV, and TLAV 
Prime. From these vaccines, there was only one vaccine 
that had been approved and licensed to be consumed in 
endemic areas, namely CYD-TDV (Dengvaxia) (Deng 
et al. 2020). In addition, there were two vaccines that 
had undertaken phase III clinical trials. Many studies 
had examined the efficacy of dengue vaccines.  
 
In this review, we discussed vaccines that had been 
approved, namely CYD-TDV and vaccines in phase III 
clinical trials, TDV (TAK-003), and TV003/TV005 
(LATV/Butantan-DV/TetraVax-DV), because many 
studies in the clinical trials showed promising results, 
where the live attenuated vaccine provided the 
advantage to stimulate and neutralize antibodies in 
humans than other types of vaccines, such as 
recombinant subunit vaccines (triggering a balanced 
immune response, problems of endotoxin 
contamination, and improper protein folding), and DNA 
vaccines (low immunogenicity), and vaccines with 
relatively low production prices that generally only 
required a single dose to provide protection, and had 
shown satisfactory results for other diseases caused by 







CYD-TDV (Chimeric Yellow fever 17D Virus-
Tetravalent Dengue Vaccine) is a live attenuated, 
recombinant tetravalent vaccine developed by Sanofi 
Pasteur and has been licensed in endemic countries in 
Asia and Latin America under the trade name 
Dengvaxia. This vaccine has been through phase I-III 
clinical trials involving more than 45,000 participants 
from 16 countries before licensed (Pinheiro-Michelsen 
et al. 2020). This vaccine is a quadrivalent combination 
of four monovalent chimeric attenuated viruses that 
comprise the prM (pre-membrane) and E (envelop) 
sequence of each DENV serotype grafted on to the 
nonstructural protein backbone of YF17D (yellow fever 
virus vaccine strain). The live attenuated vaccine, CYD-
TDV works as an agent of RNA replication, so that it 
stimulates the response of the humoral and induces 
controlled stimulation of dendritic cells and other 
immune responses. The strains used in CYD-TDV are 
genetically and phenotypically stable, non-hepatotropic 
and less neurovirulent than the strains used in YFV 17D 
(Wang et al. 2020, Collins & Metz 2017). The structure 
of this vaccine can be seen in Figure 1. This vaccine is 
given 3 times with a length sequence of 6 months, 
because in previous studies, seroconversion in vaccine 
recipients with 3 doses could reach up to 100% 
compared to 2 doses which only reached 92% (Pinheiro-
Michelsen et al. 2020). 
 
 




Table 1. Differences of three vaccines in this review 
 
 CYD-TDV TAK-003 TV003/TV005 
Phase IV (licensed) III III 
Age 9 - 45 years old (SAGE) Phase III Studies: 2-60 years 
olds 
Phase III Studies: 12 -70 
years olds  
Dosage 3 dosage, 6 months apart 2 dosage, 3 months apart Single dose 
Administration Subcutaneous Subcutaneous Subcutaneous 
Duration Protection Up to 5 years in seropositive Over 3 years At least 1 years* 
Reaction Seroconversion with 
neutralizing antibodies 
Seroconversion with 
neutralizing antibodies and 
inducing cellular immune 
responses 
Seroconversion with 
neutralizing antibodies and 
inducing cellular immune 
responses 
Serostatus Must be given to seropositive 
persons 
Regardless serostatus Regardless serostatus 
Safety No serious side effects, must 
be given to seropositive 
persons 
No serious side effects No serious side effects, most 
side effect are Rash 
Overall Efficacy ± 59.2% ± 80.6% Tetravalent neutralizing 
response 76% 
Efficacy to Seropositive ± 76% ± 82.2% No data* 
Efficacy to Seronegative ± 39% ± 74.9% No data* 
Efficacy for DENV1 ± 54.7% ± 73.7% No data* 
Efficacy for DENV2 ± 43% ± 97.7% No data* 
Efficacy for DENV3 ± 71.8% ± 62.6% No data* 
Efficacy for DENV4 ± 76.9% ± 63.3% No data* 
*need more data from future studies 
 
There are several factors that can affect the efficacy of 
this vaccine, including age, virus serotype and vaccine 
recipient serostatus (Hadinegoro et al. 2015). In its 
development, in phase IIb clinical trials in Thailand and 
phase III clinical trials in Asia and Latin America, this 
vaccine showed protection against DENV3 and also 
DENV4, moderate protection against DENV1, but it did 
not provide good protection for DENV2 with the level 
of efficacy protection against each serotype was 54.7% 
(DENV1), 43.0% (DENV2), 71.8% (DENV3), and 
76.9% (DENV4). Overall, the level of efficacy of 
protection against all DENV within 1 year after the 
administration of the third dose vaccine was 59.2% 
(Collins & Metz 2017). 
 
The serostatus of vaccine recipients also affects the 
efficacy of this vaccine, whereby vaccine recipients who 
have previously been infected with one of the DENV 
serotypes have better results (more effectively) than 
those that have never been infected. This indicates that 
CYD-TDV is better suited to improve and expand the 
existing immunity rather than provoking or incurring 
protection against all DENV serotypes in individuals 
who have never been infected previously (Collins & 
Metz 2017). This can occur, because the vaccine may 
play a role in stimulating the existing immune memory. 
 
In a case-cohort study on the effect of serostatus on 
vaccine safety and efficacy concluded that CYD-TDV 
protected against severe dengue and hospitalized for 
dengue in individuals who had been previously infected 
(seropositive), whereas inversely to those who had 
never been infected previously (seronegative) (Sridhar 
et al. 2018). With the use of CYD-TDV, seronegative 
individuals aged 9-16 years had a hazard ratio of 1.41 
(95% confidence interval [CI] 0.74-2.68) for hospital 
admission due to dengue, while seropositive had a 
hazard ratio of 0.21 (95% CI 0.14 - 0.31). In the case of 
severe dengue exposure, the hazard ratio for individuals 
with seronegative is 2.44 (95% CI 0.47 - 12.56), while 
that in seropositive is 0.16 (95% CI 0.07 - 0.37). This 
study also examined individuals aged 2 - 8 years, and 
those with seronegative had a hazard ratio of 1.95 (95% 
CI 1.19 - 3.19) for hospital admission due to dengue, 
while seropositive had a hazard ratio of 0.5 (95% CI 
0.33 - 0.77).  
 
In the case of severe dengue exposure, the hazard ratio 
for individuals with seronegative was 3.31 (95% CI 0.87 
- 12.54), while that in seropositive was 0.58 (95% CI 
0.26 - 1.30) (Sridhar et al. 2018). From this study, the 
administration of these vaccines will be more effective 
in individuals with age above 9 years and also has 
seropositive status. Other studies also showed that the 
risk of hospitalization due to dengue and risk of severe 
dengue increases in the 3 - 4 years after the first dose 
due to the protection given by the vaccine that had been 
reduced or due to the disappearance of neutralizing 
antibodies and leaving only enhancing antibodies 
(Arredondo-García et al. 2018, Plotkin 2020). 
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Related to serostatus, overall efficacy of the vaccine to 
prevent symptomatic dengue in individuals with 
seronegative was 39% (individuals over 9 years old) and 
19% (individuals aged 2-8 years). Efficacy in 
individuals with seropositive status was 76% 
(individuals over 9 years) and 60% (aged 2-8 years) 
(Sridhar et al. 2018, World Health Organization 2018). 
In regard to age, a study in Asia showed a higher 
efficacy in children over 9 years of age from children 
aged 2 - 5 years (Da Silveira 2019). Similarly, another 
study stated that the efficacy of the vaccine to prevent 
symptomatic dengue in children over 9 years was 65.6% 
compared to those under 9 years (44.6%) (Hadinegoro 
et al. 2015).   
 
The duration of protection that CYD-TDV could 
provide was at least 5 years for those with seropositivity 
(Wang et al. 2020, Sridhar et al. 2018). This vaccine is 
also relatively safe compared to other vaccines given to 
children (e.g., diphtheria and tetanus vaccines) because 
it has fewer side effects. However, as explained above, 
the use of this vaccine in those with seronegative can 
increase the risk of being hospitalized and suffering 
from severe dengue. This is probably because the CYD-
TDV vaccine is partially mimics primary infection, so 
that it plays a role in antibody- dependent enhancement 
(ADE) for a second infection (Sridhar et al. 2018, 
Swaminathan & Khanna 2019, Harenberg et al. 2016). 
Giving children under 9 years old also increases the risk 
of hospital admission and suffering severe dengue. 
However, the mechanism is still unclear (Deng et al. 
2020, Collins et al. 2017). 
 
In the updated recommendation from SAGE (Strategic 
Advisory Group of Experts) in 2018, World Health 
Organization (2018) informed that this CYD-TDV 
vaccine was given only to 9-45 years old with 
seropositive status (thus pre-vaccine screening is 
necessary), because it could increase the risk of hospital 
admission and severe dengue exposure in seronegative 
individuals. In addition, as of 1st May 2019, the Food 
and Drug Administration (FDA) indicated this vaccine 
was only for individuals 9-16 years with a history of 
previous dengue infection that had been proven by 




Similar to the manufacture of CYD-TDV, TAK-003 
replaces YF17D with DENV2 PDK-53 (laboratory-
derived attenuated virus). DENV2 PDK-53 was chosen, 
because a study showed that this strain even used in 
recombine remains replicate uniformly and also 
relatively safe (Pinheiro-Michelsen et al. 2020). Also, 
because it used the DENV2 strain, there was a 
nonstructural (NS) DENV2 protein in this vaccine 
(Wilder-Smith 2020). To get immunity against all 
serotypes, prM and E proteins from DENV1, DENV3, 
and DENV4 have been replaced to DENV2 PDK-53 
genetic backbone to get vaccine strains for each 
serotype (TDV-1, TDV-2, TDV-3, and DENV4 TDV-
4). TAK-003 was a combination of TDV 1-4 developed 
by Takeda Vaccines (Biswal et al. 2019). The structure 
of this vaccine can be seen in Figure 2. 
 
Similar to CYD-TDV as a live attenuated vaccine, 
TAK-003 acts as an agent of RNA replication that can 
stimulate humoral and cellular immune systems. In 
addition, this TAK-003 vaccine generates a CD8 + pool 
of NS1, NS3, and NS5 reactive T cells capable of 
producing IFN-γ, TNF-α, and to a lesser extent IL-2 
upon ex vivo restimulation which may arise due to the 
presence of NS proteins causing cross-reactive T-cell 
mediated responses to broad protection against dengue 
(Wang et al. 2020, Wilder-Smith 2020, Waickman et al. 
2019, Prompetchara et al. 2020, Sáez-llorens et al. 
2017). This vaccine showed seroconversion rates of 84 -
100% for DENV1, 96 - 100% for DENV2, 83 - 100% 
for DENV3, and 33 - 77% for DENV4 (Pinheiro-
Michelsen et al. 2020).  
 
Other studies also proved that the overall 
seroconversion (all serotypes) for this vaccine was 88% 
in those with seronegative and 97% in those with 
seropositive (Macias et al. 2020). TAK-003 vaccine is 
given twice with an interval of three months, because 
giving a second dose could increase immunity to 
DENV3 and DENV4 especially in those with 
seronegative baseline (Sáez-llorens et al. 2017, Sáez-
llorens et al. 2017). This vaccine is currently still in 
phase III clinical trials in Asia and Latin America. 
 
A study by Shibadas et al in phase III clinical trials with 
subjects aged 4-16 years, found that the efficacy of this 
vaccine to prevent virologically confirmed dengue 
(which was confirmed through RT-PCR testing) was 
80.6% (95% CI 73.8 - 85.6) (Biswal et al. 2019). 
Another study in phase II clinical trials also reported the 
relative risk (Rr) for the occurrence of virologically 
confirmed dengue in TAK-003 recipient individuals was 
0.35 (CI 0.19 - 0.65) (Tricou et al. 2020). Regarding the 
type of DENV serotype, in contrast to CYD-TDV, this 
vaccine showed a high efficacy against DENV2 
(efficacy 97.7%) with a different efficacy for DENV1 
(73.7%), DENV3 (62.6%), and DENV4 (63.2%) 
(Biswal et al 2019). 
 
In addition to children aged 4 - 16 years in a phase I 
clinical trial, Chukiat et al (in Sirivichayakul et al. 2015) 
showed that this vaccine could induce immunity against 
all four DENV serotypes in individuals aged 1.5 - 45 
years both with seropositive and seronegative. 
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Regarding the serostatus of vaccine recipient 
individuals, there were differences in efficacy with 
seropositive and seronegative people, but this difference 
was not as great as CYD -TDV. The efficacy of this 
vaccine against individuals with seronegative was 
74.9% and against seropositive was 82.2% (Biswal et al. 
2019). In the same study, the efficacy of this vaccine to 
prevent hospital admission due to dengue was 95.4% 
(95% CI 88.4 - 98.2%), where the efficacy in 
seronegative individuals was 97.2% and in seropositive 
individuals 94.4%. This is interesting to note, because 
the efficacy in seronegative sufferers is higher than that 
of seropositive, so that this vaccine may be suitable for 
use with seronegative compared to CYD -TDV. 
 
Two studies with phase III clinical trials within 48 
months, had shown that this vaccine provided a long-
term antibody persistence with evidence of high levels 
of antibodies above the baseline (Tricou et al. 2020, 
Biswal et al. 2020). Other studies had also shown that 
this vaccine could provide protection for at least 3 years 
after the first dose as evidenced by the presence of 
antibody titers on peripheral blood tests. Even after 3 
years, seropositivity rates for DENV1, 2, 3 were still 
high (88 - 97%) and moderate for DENV4 (56%) 
(Sirivichayakul et al. 2020).  
 
Regarding the safety of using TAK- 003, some studies 
had shown that this vaccine could be well tolerated and 
classified as safe to use as proven by the incidence of 
side effects that are relatively small in the vaccine and 
control group. From the study with a total of 20, 078 
subjects (13, 380 vaccine recipients and 6,687 controls) 
who experienced serious side effects were 1 person 
from the vaccine group and 4 people from the control 
group (2 people had hypersensitivity, 2 were diagnosed 
with dengue, and 1 was diagnosed with dengue 
hemorrhagic fever) (Biswal et al. 2019). 
 
All previous data may undergo a change later, because 
the vaccine is still in the clinical trial phase. Further 
studies were necessary to evaluate the final results of 
this vaccine. However, this vaccine remains a high 
efficacy to prevent dengue and also hospitalization due 
to dengue, including in children under 9 years and 
regardless of serostatus. 
 
TV003 / TV005 
 
The second vaccine that is currently in phase III clinical 
trial phase is TV003 / TV005 which is also a life 
attenuated vaccine. This vaccine was developed by the 
Laboratory of Infectious Disease (LID) of the National 
Institute of Allergy and Infectious Diseases (NIAID), 
which is also licensed by manufacturers from Brazil 
(Butantan Institute), Vietnam (Vabiotech), India 
(Panacea Biotech and Serum Institute of India), and 
global licensed by Merck & Co (Whitehead 2016) This 
vaccine is a live attenuated tetravalent vaccine (LATV) 
which is a combination of four attenuated recombinant 
monovalent DENV: rDENV1∆30, rDENV2/4∆30, 
rDENV3∆30/31, dan rDENV4∆30 (Pinheiro-Michelsen 
et al. 2020, Deng et al. 2020, Swaminathan & Khanna 
2019). Figure 1C provides the structure of this vaccine. 
 
This attenuated virus was created using recombinant 
DNA technology by removing nucleotides from 3' 
untranslated regions (3'UTR) from each strain of 
DENV. This region was chosen as a target, because it 
played an important role in RNA replication (Pinheiro-
Michelsen et al. 2020). Of the four components, one 
component is chimeric strain (rDENV2 / 4∆30) which is 
made by replacing prM and E protein from the 
























Figure 1. Structure of: (a) CYD -TDV (Dengvaxia); (b) TAK -003; (c) TV003 / TV005 
Source: (Pinheiro-Michelsen et al. 2020, Collins & Metz 2017, World Health Organization, 2018)
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Because this vaccine is made with three components of 
the dengue virus mutation, i.e. rDENV1∆30, 
rDENV3∆30/31, and rDENV4∆30, this vaccine also 
contains the same non-structural protein as the 
nonstructural protein of "wild" DENV 1, DENV 3, and 
DENV 4, so that this vaccine also stimulates cellular 
immune responses (T cells) besides producing 
neutralizing antibodies (Pinheiro-Michelsen et al. 
2020, Whitehead 2016, Durbin & Gubler 2019). 
 
The difference from TV003 and TV005 is the doses of 
one component (rDENV2/ 4∆30), on TV003 each 
component has a dose of 103 PFU (Plaque Forming 
Unit), while on TV005 the dose of rDENV2/ 4∆30 
increased to 104 PFU (Pinheiro-Michelsen et al. 2020, 
Whitehead 2016). This vaccine is a single dose, 
because in the study, a second dose after 6 or 12 
months did not trigger an increase in antibody titers 
and cellular response to any DENV serotype 
significantly, which proved that a single dose alone 
was sufficient to prevent virus replication and protect 
from disease with sufficient neutralizing antibody 
responses (Kallas et al 2020, Whitehead et al 2020, 
Kirkpatrick et al 2015) 
 
.Efficacy data of this vaccine is still not available. A 
study by Whitehead (2016) showed that tetravalent 
immune responses to TV003 were 87% in those who 
had been exposed to flavivirus before, and 66% in 
those who had never been exposed. The frequency of 
seroconversion of each serotype also varies, namely 
89%, 95%, 97%, 100% for DENV 1, 2, 3 and 4 in 
those who had been exposed to flaviviruses. Those 
who had never been exposed were 95%, 67%, 98%, 
100% for DENV 1, 2, 3, and 4 (Whitehead et al 2017). 
A recent study showed that the frequency of tetravalent 
neutralizing antibodies was 76% (Kallas et al 2020). In 
addition, there were other studies comparing TV003 
and TV005 resulting in tetravalent immune responses 
with TV003 were 74% and increased to 90% with 
TV005. Besides, the specific immune response for 
DENV2 also increased from 76% (TV003) to 97% 
(TV005), whereas for other serotypes, it was not much 
different (Kirkpatrick et al. 2015). 
 
Regarding safety, the use of the TV003/ TV005 
vaccine was classified as safe, because previous studies 
did not find serious side effects. Most of the side 
effects that appeared and were also significantly 
different from the control group were rash (66% - 76% 
of total vaccine recipients), where these effects could 
disappear without treatment intervention. The rashes 
are generally mild, and only a few are classified as 
moderate due to pruritus. Besides, the side effects that 
arise were not also influenced by the initial serostatus 
of the vaccine recipient (Kallas et al 2020, Whitehead 
et al 2017, Kirkpatrick et al 2016). 
Based on previous studies, the use of TV003 / TV005 
is classified as safe, tolerable, and can provide 
protection against dengue in the recipient both 
seropositive and seronegative. We are now waiting for 
further research in phase III clinical trials to see the 
extent of efficacy from this vaccine, so that it can be 
accepted in the future community. 
 
CONCLUSION  
To date, only one vaccine has been approved and 
licensed (CYD-TDV). However, the vaccine is still 
less effective and efficient in preventing dengue, so 
that its use should be reconsidered or restricted. Many 
other promising vaccines such as TAK-003 and 
TV003/ TV005 are still in the clinical trial phase, so 
that they still cannot be fully recognized. Yet from 
various research reports, this vaccine showed 
satisfactory results in performance. In general, all of 
these dengue vaccines show a good outcome to prevent 
dengue infections. 
 
It is expected that the vaccine with one-time 
administration, independent of serostatus, and can be 
used at any age range (especially children), and 
reachable by various levels of society can be developed 
immediately. More studies on these vaccines can be 
done in the near future. In addition, further study about 
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